Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02272998 · ClinicalTrials.gov registry record · Phase 2
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
A Phase 2 study, sponsored by Sameek Roychowdhury.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02272998 is a Phase 2 study that has completed, run by Sameek Roychowdhury. The registered enrollment target is 22 participants.
The verdict
NCT02272998, a Phase 2 study, has completed, sponsored by Sameek Roychowdhury.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase II trial studies how well ponatinib hydrochloride works in treating patients with cancer that has spread to other parts of the body (metastatic), has failed previous treatment (refractory), and has one of several alterations, or mutations, in its deoxyribonucleic acid (DNA) sequence. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether a patient's genetic alterations may affect how well ponatinib hydrochloride works.
Interventions
- OTHER laboratory biomarker analysis
- DRUG ponatinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-02-24 |
| Est. Completion | 2022-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02272998
The ClinicalTrials.gov registry entry for NCT02272998 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sameek Roychowdhury, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT02272998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02272998 about?
NCT02272998 is a clinical study titled "Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.". This phase II trial studies how well ponatinib hydrochloride works in treating patients with cancer that has spread to other parts of the body (metastatic), has failed previous treatment (refractory), and has one of several alterations, or mutations, in its deoxyribonucleic acid (DNA) sequence. Pona...
What is the current status of trial NCT02272998?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2015-02-24. Estimated completion is 2022-11-17.
What interventions are being tested in trial NCT02272998?
The interventions under investigation include: laboratory biomarker analysis (OTHER), ponatinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02272998?
This trial is sponsored by Sameek Roychowdhury, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.